NEWSROOM

Biotechnology

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oct 8, 2024

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...

Entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024

Oct 5, 2024

London, October 5, 2024 - PRISM MediaWire - Temos o prazer de compartilhar uma entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024 que acontecerá nos dias 27 e 28 de novembro em São Paulo. Newton Santana, Presidente e Diretor da BEVAP Bioenergia Nesta conversa perspicaz, Newton revela as estratégias de ponta da BEVAP para manter a liderança em inovação e sustentabilidade, ao mesmo tempo que oferece uma perspectiva...

Exclusive interview with Newton Santana, President and Director of BEVAP Bioenergy, ahead of Biofuels Brazil 2024

Oct 5, 2024

London, October 5, 2024 - PRISM MediaWire - We are pleased to share an exclusive interview with Newton Santana, President and Director of BEVAP Bioenergy, ahead of Biofuels Brazil 2024, which will take place on November 27-28 in São Paulo. Newton Santana, President and Director of BEVAP Bioenergy In this insightful conversation, Newton reveals BEVAP's cutting-edge strategies to maintain leadership in innovation and sustainability while offering a glimpse into the future of the biofuels...

Entrevista exclusiva con Newton Santana, Presidente y Director de BEVAP Bioenergía, en anticipación a Biocombustibles Brasil 2024

Oct 5, 2024

Londres, October 5, 2024 - PRISM MediaWire - Nos complace compartir una entrevista exclusiva con Newton Santana, Presidente y Director de BEVAP Bioenergía, en anticipación a Biocombustibles Brasil 2024, que se llevará a cabo los días 27 y 28 de noviembre en São Paulo. Newton Santana, Presidente y Director de BEVAP Bioenergía En esta conversación perspicaz, Newton revela las estrategias de vanguardia de BEVAP para mantener el liderazgo en innovación y sostenibilidad, al mismo tiempo que ofrece...

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024

Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. The gross proceeds to the Company from the...

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Oct 2, 2024

Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound...

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Oct 1, 2024

Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation....

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting

Sep 30, 2024

Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September 30, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading MedTech company focused on the development, manufacture and commercialization of placental-derived biologics, announces the filing of a Form 10 registration statement (the “Registration...

Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)

Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)

Sep 30, 2024

Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific...

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

Sep 25, 2024

NEW YORK, September 25, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC)....

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Sep 24, 2024

PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with...

Digital Utilities Ventures Reports Strong Fiscal Year 2024 – Advancing Leadership in Green Technologies

Digital Utilities Ventures Reports Strong Fiscal Year 2024 – Advancing Leadership in Green Technologies

Sep 23, 2024

MANKATO, MN, September 23, 2024 - PRISM MediaWire - Digital Utilities Ventures, Inc. (OTC: DUTV), a leader in sustainable energy and environmental technologies, recently announced its financial results and corporate progress for the fiscal year ended May 31, 2024. The company demonstrated significant growth and strategic advancements, emphasizing its commitment to innovation and sustainable environment protecting technologies. Financial Highlights: Revenue Growth: The company reported net...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024

NEW YORK, September 13, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform,...

Projetos de destaque da indústria de biocombustíveis no Brasil em 2024

Sep 12, 2024

Projetos de destaque da indústria de biocombustíveis no Brasil em 2024 Solicite a lista completa New York, September 2024 - PRISM MediaWire -Em preparação para o Fórum Internacional de Investimentos em Biocombustíveis Brasil 2024, a Vostock Capital preparou um relatório que inclui a lista completa dos projetos de destaque da indústria de biocombustíveis no Brasil, que serão abordados em detalhe durante o evento. Entre os projetos: EXPANSÃO DA PRODUÇÃO DE ETANOL Empresa: Atvos, Investimento:...

Proyectos emblemáticos de la industria de biocombustibles en Brasil 2024

Sep 12, 2024

Proyectos emblemáticos de la industria de biocombustibles en Brasil 2024 Solicite la lista completa New York, septiembre 2024 - PRISM MediaWire - Antes del Foro Internacional de Inversiones Biofuels Brazil 2024, Vostock Capital ha preparado un informe que presenta la lista completa de los proyectos emblemáticos de la industria de biocombustibles en Brasil, que se discutirán más a fondo en el evento. Entre los proyectos: • EXPANSIÓN DE PRODUCCIÓN DE ETANOL Empresa: Atvos, Inversión: US $920 M •...

Flagship projects of Biofuels industry in Brazil 2024

Sep 12, 2024

Flagship projects of Biofuels industry in Brazil 2024 Request the full list New York, September 2024 - PRISM MediaWire - Before International Investment Forum Biofuels Brazil 2024, Vostock Capital has prepared a report featuring the complete list of flagship projects of the Biofuels industry in Brazil, which will be further discussed at the event.Among the projects: ETHANOL PRODUCTION EXPANSION Company: Atvos, Investment: US $920 M CORN ETHANOL IN CAMPO MOURAO Company: Coamo...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Sep 11, 2024

Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA., September 11, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Sep 9, 2024

Early Pilot Study Data from Veteran Volunteers is Compelling - Part B Jackson Center, PA September 9, 2024 – PRISM MediaWire - Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A. This Part B supplements that release of a few days ago. As always reach out to us if you have any comments or thoughts. Good or bad, we appreciate them! The PTSD market is evolving. It is also...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Added to PRISM Emerging Medical Devices Index

Sep 6, 2024

Company's industry-first technology addresses chronic low back pain Aclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index,...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Sep 4, 2024

Early Pilot Study Data from Veteran Volunteers is Compelling Jackson Center, PA September 4, 2024 - PRISM MediaWire - Halberd Corporation (OTC: HALB) To our shareholders: As promised, this is the second of three Press Releases on our recent progress. If you have not had a chance to review that last one, on the good news on our Tri-aX™ Nasal Spray for TBI, please do. This one follows the same process. This Press Release is focused on LDN+, as related to Post Traumatic Stress Disorder (PTSD) and...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Sep 4, 2024

Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and...

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

Aug 29, 2024

Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, will present at the H.C. Wainwright 26th Annual Global Investment Conference held on September 9th through 11th in New York City at the Lotte Palace Hotel....

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Aug 27, 2024

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright’s conference is for qualified investors, and Lipella will be giving a virtual...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Corp. Issues Letter to Shareholders

Aug 26, 2024

JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax™ TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

Aug 26, 2024

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Aug 22, 2024

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)

Aug 21, 2024

New York, NY. August 21, 2024 - ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke(“TTS”)regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Aug 21, 2024

LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases 5th International Consultation on Interstitial Cystitis Japan runs Aug. 21-23 in Kyoto Pittsburgh, PA, August 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Appoints New CFO

Aug 19, 2024

New York, NY, August 19, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company’s Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. “Jeff LeBlanc is a highly experienced senior executive, and we...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

Aug 15, 2024

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S. New York, NY, August 15, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging and age-related diseases; today announced the grant and issuance of U.S. Patent No. 12,036,268 (“the 268 patent”) covering the secreted RNA splice variant of the human...